Recent submissions
Now showing items 321-340 of 1130
-
Phase I Trial of DNA Methyltransferase Inhibitor Guadecitabine Combined with Cisplatin and Gemcitabine for Solid Malignancies Including Urothelial Carcinoma (SPIRE).
(AMER ASSOC CANCER RESEARCH, 2021-04-01)PURPOSE: Preclinical data indicate that DNA methyltransferase inhibition will circumvent cisplatin resistance in various cancers. PATIENT AND METHODS: SPIRE comprised a dose-escalation phase for incurable metastatic solid ... -
Treatment Outcomes for Small Cell Carcinoma of the Bladder: Results From a UK Patient Retrospective Cohort Study.
(ELSEVIER SCIENCE INC, 2021-07-15)PURPOSE: Small cell carcinoma of the bladder (SCCB) is rare, accounting for less than 1% of all bladder carcinomas. It is aggressive, and outcomes are poor as a result of its early metastatic spread. Owing to its rarity, ... -
Hypofractionated Stereotactic Ablative Radiotherapy for Recurrent or Oligometastatic Tumours in Children and Young Adults.
Aims Cancer remains a leading cause of death in children and adolescents in the developed world. Despite advances in oncological management, rates of primary treatment failure remain significant. Radiation of recurrent or ... -
Abiraterone in "High-" and "Low-risk" Metastatic Hormone-sensitive Prostate Cancer.
(ELSEVIER, 2019-12-01)BACKGROUND: Abiraterone acetate received licencing for use in only "high-risk" metastatic hormone-naïve prostate cancer (mHNPC) following the LATITUDE trial findings. However, a "risk"-related effect was not seen in the ... -
Adult soft tissue myoepithelial carcinoma: treatment outcomes and efficacy of chemotherapy.
(OXFORD UNIV PRESS, 2019-12-27)Soft tissue myoepithelial carcinomas are a rare, malignant subgroup of myoepithelial tumours mostly arising in the extremities with equal predilection for women and men. The mainstay of management of localised disease is ... -
Capturing Global Spatial Context for Accurate Cell Classification in Skin Cancer Histology
(SPRINGER INTERNATIONAL PUBLISHING AG, 2018-01-01) -
Pattern of Progression after Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Nodal Recurrences.
Aims To report the relapse pattern of stereotactic body radiotherapy (SBRT) for oligorecurrent nodal prostate cancer (PCa).Materials and methods PCa patients with ≤3 lymph nodes (N1/M1a) at the time of recurrence were ... -
Genetic predisposition to prostate cancer: an update.
(SPRINGER, 2021-01-24)Improvements in DNA sequencing technology and discoveries made by large scale genome-wide association studies have led to enormous insight into the role of genetic variation in prostate cancer risk. High-risk prostate ... -
Evaluation of diffusion-weighted MRI and (18F) fluorothymidine-PET biomarkers for early response assessment in patients with operable non-small cell lung cancer treated with neoadjuvant chemotherapy.
(Oxford University Press (OUP), 2019-01-01)OBJECTIVE: To correlate changes in the apparent diffusion coefficient (ADC) from diffusion-weighted (DW)-MRI and standardised uptake value (SUV) from fluorothymidine (18FLT)-PET/CT with histopathological estimates of ... -
Dose verification of dynamic MLC-tracked radiotherapy using small PRESAGE (R) 3D dosimeters and a motion phantom
(IOP PUBLISHING LTD, 2019-01-01) -
Artificial intelligence and digital pathology: Opportunities and implications for immuno-oncology.
(ELSEVIER, 2021-02-06)The field of immuno-oncology has expanded rapidly over the past decade, but key questions remain. How does tumour-immune interaction regulate disease progression? How can we prospectively identify patients who will benefit ... -
Stereotactic radiotherapy with focal boost for intermediate and high-risk prostate cancer: Initial results of the SPARC trial.
(ELSEVIER IRELAND LTD, 2020-11-01)INTRODUCTION: Dose escalation to dominant intraprostatic lesions (DILs) is a novel method to increase the therapeutic ratio in localised prostate cancer. The Stereotactic Prostate Augmented Radiotherapy with Cyberknife ... -
Inclusion of a Charge Sharing Correction Algorithm Into an X-Ray Photon Counting Spectral Detector Simulation Framework
(IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC, 2021-07-01) -
The Effects of Spectral X-Ray Photon Counting Detector Parameters on Detector Performance: Thickness and Pitch
(IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC, 2020-01-01) -
Delayed contrast dynamics as marker of regional impairment in pulmonary fibrosis using 5D MRI - a pilot study.
(BRITISH INST RADIOLOGY, 2020-09-01)OBJECTIVE: To analyse delayed contrast dynamics of fibrotic lesions in interstitial lung disease (ILD) using five dimensional (5D) MRI and to correlate contrast dynamics with disease severity. METHODS: 20 patients (mean ... -
What's New for Clinical Whole-body MRI (WB-MRI) in the 21st Century.
(BRITISH INST RADIOLOGY, 2020-11-01)Whole-body MRI (WB-MRI) has evolved since its first introduction in the 1970s as an imaging technique to detect and survey disease across multiple sites and organ systems in the body. The development of diffusion-weighted ... -
Audit feasibility for geometric distortion in magnetic resonance imaging for radiotherapy.
(ELSEVIER, 2020-07-01)BACKGROUND AND PURPOSE: Magnetic Resonance Imaging (MRI) is increasingly being used in radiotherapy (RT). However, geometric distortions are a known challenge of using MRI in RT. The aim of this study was to demonstrate ... -
New target volume delineation and PTV strategies to further personalise radiotherapy.
(IOP PUBLISHING LTD, 2021-02-25)Target volume delineation uncertainty (DU) is arguably one of the largest geometric uncertainties in radiotherapy that are accounted for using planning target volume (PTV) margins. Geometrical uncertainties are typically ... -
Development and validation of a follow-up methodology for a randomised controlled trial, utilising routine clinical data as an alternative to traditional designs: a pilot study to assess the feasibility of use for the BladderPath trial.
(BMC, 2020-10-31)BACKGROUND: Bladder cancer outcomes have not changed significantly in 30 years; the BladderPath trial (Image Directed Redesign of Bladder Cancer Treatment Pathway, ISRCTN35296862) proposes to evaluate a modified pathway ...